Vitamin D levels in patients with chronic hepatitis B
Cumali Efe, Tugrul Purnak, Ersan Ozaslan – 6 December 2013
Cumali Efe, Tugrul Purnak, Ersan Ozaslan – 6 December 2013
Ulrike A. Köhler, Svitlana Kurinna, Dominik Schwitter, Andrea Marti, Matthias Schäfer, Claus Hellerbrand, Tobias Speicher, Sabine Werner – 6 December 2013 – The nuclear factor erythroid‐derived 2, like 2 (Nrf2) transcription factor is a key regulator of the antioxidant defense system, and pharmacological activation of Nrf2 is a promising strategy for prevention of toxin‐induced liver damage. However, the consequences of Nrf2 activation on liver regeneration (LR) have not been determined.
Chiun Hsu, Pei‐Jer Chen, Ann‐Lii Cheng – 6 December 2013
Jay A. Graham, James V. Guarrera – 4 December 2013
David Olagnier, John Hiscott – 4 December 2013
Nedim Hadžić, Roshni Vara – 29 November 2013
Tomoharu Yoshizumi, Toru Ikegami, Yuki Bekki, Mizuki Ninomiya, Hideaki Uchiyama, Tomohiro Iguchi, Yo‐Ichi Yamashita, Hirofumi Kawanaka, Ken Shirabe, Yoshihiko Maehara – 29 November 2013 – The limitations of donor age, graft size, and the Model for End‐Stage Liver Disease (MELD) score have not been apparent in living donor liver transplantation (LDLT). Our team developed a formula for predicting graft survival after LDLT; the formula includes the graft weight, donor age, MELD score, and portosystemic shunt status.
Seisuke Sakamoto, Mureo Kasahara, Koichi Mizuta, Tatsuo Kuroda, Takahito Yagi, Tomoaki Taguchi, Yukihiro Inomata, Koji Umeshita, Shinji Uemoto, for the Japanese Liver Transplantation Society – 29 November 2013 – Recently, liver transplantation (LT) has been increasingly performed for unresectable hepatoblastoma (HB) with acceptable results. We conducted a national survey of cases undergoing living donor liver transplantation (LDLT) for HB to evaluate their outcomes.
Eyal Shemesh, Lawrence C. Kleinman, Elizabeth A. Howell, Rachel Annunziato – 29 November 2013